Protecting Patient Access to Physician-Administered Drugs Act; create.
HB17 creates the “Protecting Patient Access to Physician-Administered Drugs Act” to protect access to prescription drugs that must be administered by a health care provider rather than self-administered by the patient. The bill states that its purpose is to preserve patient choice and ensure that health insurance issuers do not interfere with access to covered physician-administered drugs and related services. It applies to covered persons under health insurance plans and defines key terms such as health insurance issuer, pharmacy benefit manager, participating provider, and physician-administered drug.
The bill prohibits a health insurance issuer, pharmacy benefit manager, or their agents from refusing to authorize, approve, or pay participating providers for covered physician-administered drugs and related services when medical necessity criteria are met. It also bars insurers from imposing extra penalties or fees on patients beyond normal plan cost-sharing when the drug is obtained from a participating provider. The bill further requires that provider agreements be read to allow payment even when the provider obtains the drug from a non-participating pharmacy, so long as federal Drug Supply Chain Security Act requirements are met. Payment must be made at the contract rate, or at wholesale acquisition cost if no rate is specified.
HB17 also makes violations of the act a violation of Mississippi’s Consumer Protection Act, exposing violators to investigative demands, private actions, remedies, and penalties. It amends Section 75-24-5 of the Mississippi Code to add violations of this new act to the list of unfair or deceptive trade practices. Any conflicting contract term is declared void and unenforceable in Mississippi, giving the bill direct effect on insurer-provider agreements and pharmacy benefit manager practices.
The overall sentiment around the bill appears strongly supportive and largely noncontroversial. It passed the House 115-0 and the Senate 48-0, indicating unanimous approval in both chambers. The lack of recorded committee transcript discussion suggests there was little public dispute or that the measure was viewed as a technical patient-access and consumer-protection bill.
The main policy issue embedded in the bill is the balance between patient access and insurer/pharmacy benefit manager control over drug distribution and reimbursement. Supporters would likely view it as protecting patients and providers from network restrictions or reimbursement denials, while any potential concern would center on insurer cost management, contract interference, and the expansion of consumer-protection liability. However, no recorded opposition appears in the voting history provided.
HB17 adds a new statutory framework governing coverage and reimbursement for physician-administered drugs under health insurance plans in Mississippi. It directly affects health insurance issuers, pharmacy benefit managers, participating providers, and covered persons by limiting network-based restrictions, requiring payment for medically necessary covered drugs, and invalidating contrary contract terms. It also expands the Consumer Protection Act to cover violations of this new law, increasing enforcement exposure for insurers and related entities.
The bill’s sentiment is overwhelmingly positive and bipartisan based on the recorded votes. It passed both chambers unanimously, suggesting broad agreement that the measure protects patient access and clarifies payment obligations for provider-administered drugs. No committee debate or recorded dissent is available in the provided materials, and the vote totals indicate little to no controversy at the legislative level.
The most notable point of contention, though not reflected in the votes, is the bill’s restriction on insurer and pharmacy benefit manager discretion over authorization, payment, and network sourcing for physician-administered drugs. Insurers and PBMs could be concerned that the bill limits utilization management, overrides contract terms, and potentially increases costs by requiring payment at contract rates or wholesale acquisition cost. On the other side, patients and providers would likely support the bill as a safeguard against access barriers, surprise fees, and reimbursement denials.